X

ONECare Population Health Academy – Join For Free

"*" indicates required fields

Already a member of the OPEN MINDS network? Click here to login.
Name*
Address*
This field is hidden when viewing the form
This field is hidden when viewing the form
MM slash DD slash YYYY
This field is hidden when viewing the form
This field is hidden when viewing the form

X

Oops! You need to be logged in to use this form.

Utah-Based Health Plan SelectHealth To Cover Pear Therapeutics’ Prescription Digital Therapeutic For Opioid Use Disorder Treatment

|

By OPEN MINDS Circle

SelectHealth, a health plan with members in Utah, Idaho, and Nevada is covering the Pear Therapeutics reSET-O prescription digital therapeutics (PDTs) for opioid use disorder treatment. reSET-O is approved by the U.S. Food and Drug Administration (FDA) as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for consumers 18 years or older who are currently under the supervision of a clinical professional. SelectHealth is the first health plan in Utah to cover reSET-O.

The reSET-O PDT is a 12-week (84 day) software application for mobile devices intended to increase treatment retention of consumers with opioid use disorder (OUD) in outpatient treatment. The PDT provides cognitive behavioral therapy, fluency training, and contingency management. It provides clinical professionals with access to clinical dashboards to inform in-office and telehealth visits.

Non-profit SelectHealth is a wholly owned subsidiary of Intermountain Healthcare. SelectHealth serves more than one million members. In addition to commercial and government medical plans, SelectHealth offers dental, vision, and pharmacy benefit management. SelectHealth plans are available for Medicare Advantage and Medicaid enrollees, and SelectHealth is a carrier for the Children’s Health Insurance Plan (CHIP) and the Federal Employee Health Benefits (FEHB) Plan.

Pear Therapeutics develops and markets PDTs for multiple therapeutic areas. Three of its PDTs have been authorized by the FDA for commercial use; they are reSET® for addiction treatment, reSET-O® for opioid addiction, and Somryst® for the treatment of chronic insomnia. The PDTs are designed to engage consumers in treatment and provide tracking tools for clinical professionals. Its PDTs are designed to collect real world data for use by prescribing clinical professionals and for population health management by payers and health systems.

Contact information: Meara Murphy, Senior Director, Corporate Communications, Pear Therapeutics, 201 Mission Street, San Francisco, California 94105; Email: meara.murphy@peartherapeutics.com; Website: https://peartherapeutics.com/

Contact information: Dan Nelson, Media Relations Manager, SelectHealth, 5381 S Green St., Murray, UT 84123; Email: daniel.nelson2@selecthealth.org; Website: https://selecthealth.org/